Arsanis Inc (ASNS.OQ)
15.75USD
1:30am IST
$-0.10 (-0.63%)
$15.85
$16.12
$16.16
$15.53
3,918
10,437
$27.83
$10.50
Latest Key Developments (Source: Significant Developments)
Arsanis Inc - Out Licenses Preclinical Stage E. Coli Monoclonal Antibodies
April 4 (Reuters) - Arsanis Inc
Arsanis Reports Q4 Net Loss $1.68 Per Share
March 9 (Reuters) - Arsanis Inc
Arsanis Inc Files To Say It Has Raised $20 Million In Equity Financing - SEC Filing
Dec 4 (Reuters) - Arsanis Inc
OrbiMed Advisors Reports 13.07 Percent Stake In Arsanis As Of Nov 20 - SEC Filing
Nov 30 (Reuters) - OrbiMed Advisors LLC::ORBIMED ADVISORS LLC REPORTS 13.07 PERCENT STAKE IN ARSANIS INC AS OF NOVEMBER 20 - SEC FILING .ORBIMED ADVISORS LLC - CAUSED OPI IV TO ACQUIRE COMMON STOCK OF THE ARSANIS INC FOR THE PURPOSE OF MAKING AN INVESTMENT. Full Article
Terrance G. Mcguire Reports A 13.7 Percent Stake In Arsanis Inc As Of November 20, 2017 - SEC Filig
Nov 29 (Reuters) - Arsanis Inc
New Enterprise Associates 16 L.P. Reports 14.6 Percent Stake In Arsanis As Of Nov 20
Nov 29 (Reuters) - NEW ENTERPRISE ASSOCIATES 16 L.P:NEW ENTERPRISE ASSOCIATES 16 L.P. REPORTS A 14.6 PERCENT STAKE IN ARSANIS AS OF NOVEMBER 20, 2017 - SEC FILING. Full Article
Arsanis Inc shares debut about 30 pct above IPO price
Nov 16 (Reuters) - :Arsanis Inc shares open at $13.00 in debut on the NASDAQ versus IPO price of $10.00 per share. Full Article
Arsanis prices initial public offering of 4 mln common shares at $10 per share
Nov 15 (Reuters) - Arsanis Inc
Arsanis Inc now sees IPO of 4 mln shares of common stock
Nov 15 (Reuters) - Arsanis Inc
Arsanis Inc sees IPO of up to 3.13 mln shares of common stock to be priced between $15 and $17 per share
Nov 6 (Reuters) - Arsanis Inc
BRIEF-Arsanis Inc - Out Licenses Preclinical Stage E. Coli Monoclonal Antibodies
* BB100 SECURED EXCLUSIVE,WORLDWIDE PRECLINICAL DEVELOPMENT LICENSE, OPTION TO DEVELOPMENT, COMMERCIALIZATION LICENSE, TO MABS TARGETING E. COLI Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)